| Date | Title | Description | |
|---|---|---|---|
| 27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
| 09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 28 Jul 2023 | On business and financial situation | ROVI informs on the evaluation process to obtain marketing authorisation for Risvan® | Download |
| 05 Jul 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2023 | Download |
| 26 Jun 2023 | Other relevant information | The Company informs about the dividends payment | Download |
| 14 Jun 2023 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting. | Download |
| 31 May 2023 | Other relevant information | ROVI informs about the news items that have appeared in several media today regarding ROVI’s receipt of government grants | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 May 2019 | Information on P&L | ROVI releases the first quarter 2019 results presentation | Download |
| 08 May 2019 | Information on P&L | ROVI releases the press release related to the first quarter 2019 financial results | Download |
| 07 May 2019 | Liquidity contracts and specialists | ROVI announces the signature of a new liquidity contract with Renta 4 Banco, S.A. | Download |
| 30 Apr 2019 | Liquidity contracts and specialists | ROVI announces the termination of the liquidity contract signed with JB Capital Markets, S.V., S.A.U. | Download |
| 11 Apr 2019 | Strategic agreements with third parties | The Company releases the press release related to the marketing agreement of Tetridar® in Spain | Download |